GATA-3

Product Description

GATA-3 (GATA binding protein 3) is a member of the GATA family of transcription factors. This 50 kDa nuclear protein regulates the development and subsequent maintenance of multiple tissues.^15-19 Among several other roles, GATA-3 has been identified as a key player of luminal cell differentiation in the mammary gland.¹⁸ GATA-3 appears to control a set of genes involved in the differentiation and proliferation of breast cancer.^17,18

Specifications

Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.

1. Raspollini MR, et al. The use of placental S100 (S100P), GATA3 and Napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica. 2010 Feb; 102(1):33-5.
2. Esheba GE, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009 Mar; 33(3):347-53.
3. Albergaria A, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009; 11(3):R40.
4. Kouros-Mehr H, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 2008 Feb; 13(2):141-52.
5. Voduc D, et al. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):365-73.
6. Parikh P, et al. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg. 2005 May; 200(5):705-10.
7. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
8. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.